Former Lawyer Went From $50K To $5.3M Trading Options
Slaving away for 70 hrs a week as a lawyer in Chicago, I was miserable.

I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually).

I grew my $50K into $5.3M
I'll show you how I did it here.

MSB Insider Trading (Mesoblast)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Mesoblast Insider Trading History Chart

This chart shows the insider buying and selling history at Mesoblast by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Mesoblast Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for MSB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.

Mesoblast Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/14/2022Philip FacchinaInsiderIssued200,000A$1.31A$262,000.00
6/24/2020Silviu ItescuInsiderIssued1,885,334A$3.47A$6,542,108.98
12/3/2019William (Bill) BurnsInsiderBuy32,670A$1.83A$59,786.10
See Full Table
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.

SEC Filings (Institutional Ownership Changes) for Mesoblast (ASX:MSB)

Mesoblast logo
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Read More on Mesoblast

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

10,191,278 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Mesoblast?

Mesoblast's top insider shareholders include:
  1. Philip Facchina (Insider)
Learn More about top insider investors at Mesoblast.
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.